Modern was one of the great achievers during the pandemic thanks to the development of its mRNA platformwhich was the key to the creation of the COVID-19 vaccine. But the pandemic is behind us, as are the big revenues. But the firm, with this platform in its possession, is developing medical advances against cancer that promise the recovery of income and profits in the next five years.
According to data from The Motley Fool, ARNm-4157a personalized therapeutic cancer vaccineis one of the great candidates for the company to recover the period of prosperity and profitability.
This treatment is found in phase 3 and is being tested in several types of cancer such as lung cancer, renal cell carcinoma, bladder cancer and melanoma.
Notably, in mid-phase studies, mRNA-4157 significantly reduced the risk of recurrence or death in patients with melanoma combine withKeytruda de Merckcompared to Keytruda alone.
What do the analysts say?
According to Tipranks, Moderna has the review by 20 analysts divided into 3 buys, 13 hold and 4 sells. The average price target is $39.31, with a forecast high of $198 and a forecast low of $17. The average price target represents a variation of 65.73% from Tuesday’s close.
Edward Tenthoff, Piper Sandler analystrecommends comprar with a target price in 63 dollars.
Gena Wang, Barclays analystrecommends keep with a target price in 25 dollars.
Mani Forcohar, analyst at Leerink Partnersrecommends sell with a target price in 18 dollars.
Modern It closed Tuesday’s session higher at $24.76. The 70-period moving average is above the latest candles, RSI is up at 48 points and the MACD lines are below the zero level.